Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
NCT06347159 · View on ClinicalTrials.gov ↗
Study Summary
This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with obstructive or nonobstructive hypertrophic cardiomyopathy (nHCM).
Conditions Studied
Interventions
- DRUG EDG-7500
Study Locations (20)
Massachusetts
- Massachusetts General Hospital — Boston
- Brigham and Womens Hospital — Boston
- Lahey Hospital and Medical Center — Burlington
Ohio
- The Lindner Research Center at Christ Hospital — Cincinnati
- University Hospitals Cleveland Medical Center — Cleveland
- Cleveland Clinic — Cleveland
California
- University of California, San Francisco — San Francisco
- Stanford University Hospital / Stanford Health Care — Stanford
New York
- North Shore University Hospital — Manhasset
- NYU Langone Health Medical Center - HCM Program Office (Study open to existing NYU patients only) — New York
North Carolina
- Sanger Heart and Vascular Institute — Charlotte
- Duke Health Center Arringdon — Morrisville
Georgia
- Emory Clinic — Atlanta
Michigan
- Michigan Medicine - Michigan Clinical Research Unit — Ann Arbor
Missouri
- Saint Luke's Hospital of Kansas City — Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-04-11 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06347159
The ClinicalTrials.gov registry entry for NCT06347159 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edgewise Therapeutics, which has 37 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Hypertrophic Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention — of which EDG-7500 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06347159 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Massachusetts, Ohio, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06347159 about?
NCT06347159 is a clinical study titled "A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)". This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with obstructive or nonobstructive hypertrophic cardiomyopathy (nHCM).
What is the current status of trial NCT06347159?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2024-04-11. Estimated completion is 2026-12.
What conditions does trial NCT06347159 study?
This clinical trial studies the following conditions: Hypertrophic Cardiomyopathy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06347159?
The interventions under investigation include: EDG-7500 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06347159?
This trial is sponsored by Edgewise Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06347159 being conducted?
This trial has 20 study locations across California, Georgia, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.